Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Hainan Tongyong Sanyang Pharmaceutical Co., Ltd. (referred to as "Sanyang Pharmaceutical"), has received the drug registration certificate for Nicergoline Tablets from the National Medical Products Administration, which is expected to enhance the company's product line and strengthen its position in the neurological medication sector [1]. Group 1 - Sanyang Pharmaceutical's Nicergoline Tablets are primarily used to improve motivation deficits caused by sequelae of cerebral infarction and are also applicable for vascular dementia, particularly in early treatment to enhance cognitive and memory functions, as well as to alleviate disease severity [1]. - The approval of the drug registration certificate is beneficial for enriching the company's product portfolio and further developing its presence in the neurological medication field [1]. - This development will accumulate valuable experience for the company's future generic drug development [1].

药品名称：尼麦角林片 受理号：CYHS2401567 证券代码：600056 证券简称：中国医药 公告编号：临 2026-003 号 中国医药健康产业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司海南通用三洋药业有限公司（以下简称"三洋药业"）收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的尼麦角林片（以下简称"该药品"） 《药品注册证书》，现将有关情况公告如下： 一、注册证书基本信息 (一) 尼麦角林片主要用于改善由于脑梗塞后遗症引起的意欲低下；也适用 于血管性痴呆，尤其在早期治疗时对认知、记忆等有改善，并能减轻疾病严重程 度。该药品最早由意大利法玛西亚公司（现为辉瑞公司）研发，于 1972 年 5 月 上市。该药品在国内已有原研地产化产品上市。 （二）国家药监局于 2024 年 5 月 24 日受理该药品的注册申请。 （三）截止本公告披露日，该药品累计投入约 1,336 万元人民币（未经审计） ...

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Hainan General Sanyou Pharmaceutical Co., Ltd. (referred to as "Sanyou Pharmaceutical"), has received the drug registration certificate for Nicergoline Tablets from the National Medical Products Administration [1] Group 1 - Nicergoline Tablets are primarily used to improve motivation deficits caused by sequelae of cerebral infarction [1] - The drug is also applicable for vascular dementia, particularly in early treatment, where it can enhance cognitive and memory functions and reduce the severity of the disease [1]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Hainan Tongyong Sanyang Pharmaceutical Co., Ltd. (referred to as "Sanyang Pharmaceutical"), has received the drug registration certificate for Nicergoline Tablets from the National Medical Products Administration [1] Group 1 - Nicergoline Tablets are primarily used to improve motivation deficits caused by sequelae of cerebral infarction [1] - The drug is also applicable for vascular dementia, particularly in early treatment to enhance cognitive and memory functions, and to alleviate the severity of the disease [1]

Core Insights - The pharmaceutical logistics industry is experiencing robust growth driven by national policy support, an aging population, increased health awareness, and advancements in medical technology. The "Healthy China" strategy is further enhancing the industry's development space [1][7][9]. Industry Overview - Pharmaceutical logistics is a crucial component of modern logistics, responsible for the circulation and turnover of pharmaceuticals. It encompasses seven main functions: transportation and distribution, warehousing management, packaging, circulation processing, loading and unloading, network design, and information processing [2][5][7]. Market Growth - The total value of pharmaceutical logistics in China has shown steady growth, increasing from 241.86 billion yuan in 2019 to an expected 336.66 billion yuan in 2024, with a compound annual growth rate (CAGR) of 6.84%. Projections indicate that this total will reach 357.2 billion yuan by 2025 [1][4][9]. Sales Growth of Pharmaceutical Products - The total sales of seven major categories of pharmaceutical products in China rose from 1,661.3 billion yuan in 2015 to an estimated 2,947.0 billion yuan in 2024, reflecting a CAGR of 6.58%. This expanding market size supports the demand for pharmaceutical logistics [4][9]. Industry Structure - The pharmaceutical logistics industry consists of three main segments: upstream (pharmaceutical manufacturers and equipment suppliers), midstream (logistics companies), and downstream (medical institutions, pharmacies, and patients) [5][6]. Logistics Centers and Warehousing - The number of logistics centers in the pharmaceutical logistics industry increased from 1,115 in 2017 to 1,370 in 2024, with a CAGR of 2.99%. Warehouse area expanded from 10.65 million square meters to 15.42 million square meters during the same period, with a CAGR of 5.43% [10][11]. Transportation Vehicles - The total number of specialized transportation vehicles in the pharmaceutical logistics sector is projected to reach 17,617 by 2024, with refrigerated vehicles accounting for 19.9% of the total, indicating a growing demand for cold chain logistics [12][13]. Delivery Methods and Technology - In 2024, 62.5% of deliveries in the pharmaceutical logistics industry were self-delivered, while 37.5% were outsourced. The adoption of automation and information technology is increasing, with 89.0% of companies having warehouse management systems and 83.1% using electronic tagging systems [13][14]. Key Players - Major companies in the pharmaceutical logistics sector include JD Logistics, China National Pharmaceutical Group, and various specialized logistics firms. JD Logistics reported a revenue of 153.616 billion yuan in the first three quarters of 2025, reflecting a year-on-year growth of 17.5% [14][16]. Industry Challenges - Despite the growth, the pharmaceutical logistics industry faces challenges such as high overall costs, uneven regional development, and a lack of relevant standards [17]. Future Trends - The industry is expected to evolve towards greater automation and intelligence, with AI systems optimizing logistics operations. Additionally, a shift towards full traceability and data integration is anticipated, enhancing the efficiency and responsiveness of the logistics network [18][19].

转自：前瞻产业研究院 以下数据及分析来自于前瞻产业研究院医药研发外包(CRO)研究小组发布的《中国医药研发外包（CRO） 行业市场前瞻与投资战略规划分析报告》。 行业主要上市公司：目前国内CRO行业主要的上市公司有药明康德(603259.SH)、康龙化成(300759.SZ)、泰 格医药(300347.SZ)、凯莱英(002821.SZ)、昭衍新药(603127.SH)、九洲药业(603456.SH)、皓元医药 (688131.SH)、博腾股份(300363.SZ)、成都先导(688222.SH)、药石科技(300725.SZ)等。 本文核心数据：企业主营业务收入、企业经营毛利率 1、中国CRO产业链全景梳理 中国CRO产业链贯穿研发阶段、生产阶段和产品销售整个药品生命周期，分别对应药物研发服务(CRO)、 医药生产服务(CMO/CDMO)以及医药销售服务(CSO)。研发阶段覆盖临床前与临床两大核心环节，其中临 床前主要做有关药物发现、化合物合成、合成工艺研发及制剂研发等早期基础研发工作;临床阶段主要进行 临床试验、医学统计、数据整理与数据分析等流程。生产阶段，针对不同药物类型提供生产服务，化学原 料药包含了 ...

Group 1 - Company subsidiary Hainan Tongyong Sanyang Pharmaceutical Co., Ltd. needs to pay tax arrears of approximately 21.49 million yuan and late fees of about 10.74 million yuan, while Hainan Kangli Pharmaceutical Co., Ltd. needs to pay tax arrears of approximately 21.28 million yuan and late fees of about 11.71 million yuan, totaling around 65.22 million yuan [1][2] - The tax payment does not involve any administrative penalties and will be settled as required [1] - The tax arrears and late fees will be included in the company's 2025 profit and loss, expected to impact the net profit by 65.22 million yuan [2] Group 2 - Company subsidiary Tianfang Pharmaceutical Co., Ltd. received approval for the drug Clarithromycin Tablets, which passed the consistency evaluation for generic drug quality and efficacy [4][5] - Clarithromycin is used to treat infections caused by sensitive pathogens, with a market presence since 1991 [5][8] - The total investment in the Clarithromycin project is approximately 11.79 million yuan [7] - The domestic sales of Clarithromycin in public hospitals and grassroots medical institutions were about 407 million yuan in 2024, with the company's sales at approximately 2.83 million yuan [8]

Group 1 - Huawei's rotating chairman Meng Wanzhou emphasizes the importance of resilience and professionalism in overcoming challenges and creating value in the face of the intelligent transformation wave, highlighting the need for strategic focus and organizational strength by 2026 [27] - Hengrui Medicine plans to increase R&D investment, focusing on oncology, autoimmune, and metabolic diseases, aiming to address unmet clinical needs and enhance international cooperation for global commercialization of Chinese innovative drugs by 2026 [28] - Wanhua Chemical's chairman Liao Zengtai aims to enhance operational quality and focus on technological innovation, particularly in battery materials and high-end new materials, to create a competitive advantage and develop an integrated growth model by 2026 [29] Group 2 - Muyuan Foods' chairman Qin Yinglin reflects on the company's journey from starting with 22 pigs to becoming the largest pig farming enterprise globally, emphasizing the importance of innovation and technology in achieving a dignified and efficient pig farming process by 2026 [30] - Gree Electric's chairman Dong Mingzhu commits to deepening core business and accelerating in smart equipment and new energy sectors, while focusing on green and digital transformation to enhance product quality and service for global users by 2026 [31] - Geely Holding Group's chairman Li Shufu highlights the importance of making bold decisions during critical moments, emphasizing the need to overcome challenges and maintain core values as the company approaches its 40th anniversary in 2026 [32] Group 3 - SAIC Motor's chairman Wang Xiaoqiu outlines the company's commitment to deepening reforms and focusing on intelligent and electric vehicle development, aiming for high-quality growth and user-centered innovation by 2026 [32] - Hengli Group's chairman Chen Jianhua stresses the importance of practical action and innovation in overcoming development challenges, encouraging a proactive approach to seize opportunities in the coming years [33] - LONGi Green Energy's chairman Zhong Baoshan believes the photovoltaic industry is at a pivotal moment, emphasizing the need for technological innovation to navigate challenges and capitalize on the global green energy transition [34] Group 4 - Inspur's chairman Li Jun emphasizes the transformative impact of artificial intelligence on the global economy and the importance of open collaboration to unlock AI's potential, with a focus on building a comprehensive innovation ecosystem by 2026 [35] - TCL's chairman Li Dongsheng highlights the need for strategic focus on achieving global leadership and enhancing core capabilities to drive high-quality development amid economic uncertainties in 2026 [36] - Trina Solar's co-chairman Gao Haichun emphasizes the company's evolution from a product supplier to a system-level innovator, focusing on creating solutions that transcend traditional competition by 2026 [38] Group 5 - JinkoSolar's chairman Li Xian-de discusses the potential of space photovoltaic technology as a sustainable energy solution for future AI power needs, marking the company's 20th anniversary with a vision for universal solar energy [39] - Leo Group's chairman Wang Xiangrong aims to enhance the company's strategic focus and sustainable value, emphasizing collaboration with customers and employees to achieve higher-dimensional value creation by 2026 [40] - Innovent Biologics' chairman Cui Jisong outlines the company's commitment to innovation and global expansion, aiming to launch multiple new drugs and maintain an entrepreneurial spirit in the face of uncertainty by 2026 [41]

Group 1 - Huawei's rotating chairman Meng Wanzhou emphasized the importance of resilience and professionalism in overcoming challenges and creating value, highlighting the long-term strategic opportunities presented by the wave of intelligent transformation [25] - Hengrui Medicine's chairman Sun Piaoyang announced plans to increase R&D investment, focusing on oncology, autoimmune, and metabolic diseases, while promoting international cooperation and accelerating overseas clinical trials [26] - Wanhua Chemical's chairman Liao Zengtai aims to enhance operational quality and focus on technological innovation, particularly in battery materials and high-end new materials [27] Group 2 - Muyuan Foods' chairman Qin Yinglin expressed commitment to smart pig farming and improving animal health, aiming to enhance the quality and safety of pork for consumers [28] - Gree Electric's chairman Dong Mingzhu plans to deepen the core business while accelerating in smart equipment and renewable energy sectors, emphasizing a commitment to green and digital transformation [29] - Geely Holding Group's chairman Li Shufu highlighted the importance of making bold decisions during critical moments, focusing on core values and sustainable development [30] Group 3 - SAIC Motor's chairman Wang Xiaoqiu stated the company will deepen reforms and focus on intelligent and electric vehicle development, aiming for high-quality growth [30] - Hengli Group's chairman Chen Jianhua emphasized the need for a proactive approach to overcome challenges and achieve breakthroughs in the coming years [31] - LONGi Green Energy's chairman Zhong Baoshen believes the photovoltaic industry is at a pivotal moment, with significant opportunities for innovation and growth [32] Group 4 - TCL's chairman Li Dongsheng stressed the importance of maintaining strategic focus and enhancing core capabilities to achieve high-quality development [33] - Inspur's acting chairman Li Jun highlighted the transformative impact of artificial intelligence on the economy and the need for open and collaborative innovation [35] - Trina Solar's co-chairman Gao Haichun mentioned the company's evolution from a product supplier to a solution provider, focusing on system-level product innovation [36] Group 5 - JinkoSolar's chairman Li Xian-de discussed the potential of space photovoltaic technology as a sustainable energy solution for future challenges [37] - LEO Technology's chairman Wang Xiangrong emphasized the importance of creating value beyond mere data growth, focusing on sustainable and collaborative progress [38] - Innovent Biologics' chairman Cui Jisong outlined the company's commitment to innovation and global expansion in the next decade [39] Group 6 - Fosun International's chairman Guo Guangchang highlighted the growing demand for health and wellness, emphasizing the need to leverage the company's strengths in various industries [40] - Obsidian Technology's chairman Huang Yuanhao expressed the importance of innovation in robotics and AI vision, aiming to lead in the upcoming technological revolution [41] - Volkswagen's chairman Yang Guoping emphasized the commitment to brand and innovation as the company embarks on a new journey in the "14th Five-Year Plan" [42]

Group 1: Innovation in Pharmaceuticals - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of foreign licensing transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also a historical high [1] - Among the 76 approved innovative drugs, 47 are chemical drugs, 23 are biological products, and 6 are traditional Chinese medicines, with a high proportion of domestic innovations [1] Group 2: Drug Approval and Clinical Trials - China Medical's subsidiary Tianfang Pharmaceutical received approval for clarithromycin tablets, which passed the consistency evaluation for generic drugs [2] - Microchip Biotech announced that its CS08399 tablets for treating tumors with MTAP deficiency have had their clinical trial application accepted [3] - Frontier Biotech's FB7013 injection, targeting MASP-2 for IgA nephropathy, received acceptance for its clinical trial application, marking it as a first-in-class drug [4] Group 3: Capital Market Activities - Yifang Biotechnology submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [5] - Wanyi Medical also submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan International as the exclusive sponsor [6] Group 4: Corporate Investments and Acquisitions - Yunnan Baiyao plans to invest up to 45% of its net assets in financial products in 2026 [7] - Haili Biological's subsidiary intends to acquire 51% stakes in seven dental chain companies for 61.2 million yuan, expecting to increase revenue by approximately 100 million yuan [9] Group 5: Corporate Restructuring and Legal Matters - *ST Chang Pharmaceutical announced that its restructuring investors intend to terminate the restructuring investment agreement [10] - Zai Lab entered a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, with potential milestone payments totaling up to $10.75 billion [11] - Tianyu Biotech's actual controller received a notice from the China Securities Regulatory Commission regarding an investigation into alleged illegal stock reduction [13]